PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.
about
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerClinical utility of nivolumab in the treatment of advanced melanomaPD-1/PD-L1 blockade in cancer treatment: perspectives and issuesHuman Cancer Immunotherapy with PD-1/PD-L1 BlockadePembrolizumabNivolumab in the treatment of malignant melanoma: review of the literatureThe programmed death-1 immune-suppressive pathway: barrier to antitumor immunityOvercoming T cell exhaustion in infection and cancerFrom tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsPD-1 and its ligands are important immune checkpoints in cancerImmunoregulation in Fungal DiseasesAnti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potentialThe Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaImmunosuppressive networks in the tumour environment and their therapeutic relevanceLoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaRational combinations of immunotherapeutics that target discrete pathways.Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cellsInhibitory RNA molecules in immunotherapy for cancer.Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escapeProgrammed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemiaTherapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers.Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.Prostate cancer as a model for tumour immunotherapy.The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomasCD8+ T cells regulate bone tumor burden independent of osteoclast resorption.Prostate cancer immunotherapy.Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression.Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cellsInhibitory costimulation and anti-tumor immunity.Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.Dendritic cells: tools and targets for antitumor vaccination.Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma.Checkpoint blockade in cancer immunotherapyStrategies and developments of immunotherapies in osteosarcoma
P2860
Q24685406-50562C69-059F-4E25-84F1-E46953A4DDF5Q26751268-7AC96809-F72B-4665-83CE-DC949883EFB2Q26768641-3F3DD9BC-3707-4560-ACE6-CCF185D100DCQ26786108-764E2A47-BF9B-4B90-8A29-0B009C2B7B34Q26796435-07C80D6B-0EF7-4E1D-BCB1-E7B471E45647Q26798330-1BD030E6-D58D-4D4E-8C5D-BC9D78C5B0F2Q26829847-69D40FFC-7C5E-4785-B81F-05338C84EFFFQ26829885-03956AA7-1B49-4350-91EC-7299651DC2C9Q26865532-50DCD5D2-D097-4958-8FD5-F86CE14A3D0AQ28069485-964563B0-0A0C-4317-8102-6CF834F0D6D6Q28074776-E874970D-4E0E-4958-862E-E1550B01500AQ28084942-16328FAF-F0D5-435D-B777-02F4D8ADF4D6Q28088496-F927549B-3E5F-41DE-8AB7-24434A112383Q29619244-7E793EAC-6110-462D-893D-408F69841C8DQ29620812-A25142AD-CD5C-47FC-9F49-0DE17B9E6A87Q33606144-2C04B0D3-C58E-45C8-A6A8-009AB02BFED4Q33606150-BA80DE4D-5194-437E-839B-9E233E6F0D70Q33732329-EEF99743-48FC-440B-9C91-549622CE8D7EQ34001061-9289631E-FEE6-4E77-A7B9-08BC77249F64Q34033910-C9A677E4-DE0C-4467-846C-32D87F4B2DA6Q34241893-A40E1D6D-B468-4682-B2AD-58639336B37FQ34245048-882D4D08-A4E7-405F-9C82-67616C0DDC0EQ34443923-E9F71328-F764-4917-84D1-F55EA6F442BBQ34538075-E1087F4A-DC1D-40C3-9DE7-57E16FC41CE1Q34548226-73330C38-67DF-450F-AFF0-6BB83E00F4F1Q34550012-F306890A-E665-4039-A3E6-8CCF116FF554Q34856875-81C0CA9E-9CBB-4901-B51E-43178776E3CEQ35052176-81CA096C-D11D-4740-B333-46D771772405Q35070603-AA80B04A-BB99-4697-BC2F-3D6BA19210C7Q35112793-9B1280AA-5173-4681-95FB-CAB37247DFFDQ35688425-3E7DA978-2CE7-4CF2-A7CB-654BAFECDDF3Q35742964-8E539FC8-F845-4D89-A82C-A4104040C6AFQ35824223-47A6F04E-FC23-41C2-931A-0871E67A12F5Q36016292-7D50F791-3D44-458E-9692-D4642D2F0F63Q36067524-F7BDF776-C8A6-4C63-88AA-50AD66C0EE16Q36206582-EF7F49F1-987F-4395-A713-82002FC1EB12Q36284556-0703C568-77AB-44F4-A77F-3501DD8C4EB1Q36475837-D1877DC2-E761-4D80-8201-F76B66218658Q36490768-AB662907-CE7C-4A20-8A65-6A5E3E0CC232Q36503128-DD6FCB7D-227F-46D1-96C3-C90EBCB99299
P2860
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
PD-1 blockade inhibits hematog ...... cruitment of effector T cells.
@ast
PD-1 blockade inhibits hematog ...... cruitment of effector T cells.
@en
PD-1 blockade inhibits hematog ...... cruitment of effector T cells.
@nl
type
label
PD-1 blockade inhibits hematog ...... cruitment of effector T cells.
@ast
PD-1 blockade inhibits hematog ...... cruitment of effector T cells.
@en
PD-1 blockade inhibits hematog ...... cruitment of effector T cells.
@nl
prefLabel
PD-1 blockade inhibits hematog ...... cruitment of effector T cells.
@ast
PD-1 blockade inhibits hematog ...... cruitment of effector T cells.
@en
PD-1 blockade inhibits hematog ...... cruitment of effector T cells.
@nl
P356
P1476
PD-1 blockade inhibits hematog ...... cruitment of effector T cells.
@en
P2093
Seigo Terawaki
Yoshiko Iwai
P304
P356
10.1093/INTIMM/DXH194
P50
P577
2004-12-20T00:00:00Z